Pulmonary Embolism
Also known as: PE, Blood Clot in the Lung
A pulmonary embolism (PE) is a blood clot that has lodged in an artery of the lung, almost always after breaking away from a clot in a deep vein of the leg or pelvis. It is a medical emergency: sudden breathlessness, chest pain that is worse on breathing in, a racing heart, coughing up blood or fainting means calling 911, not searching for remedies. Treated promptly with anticoagulants most people survive and recover; untreated, roughly one in three die.
Last updated November 10, 2026
Understanding Pulmonary Embolism
Pulmonary embolism is the third most common cardiovascular cause of death after heart attack and stroke. In the United States, venous thromboembolism, the combined term for deep vein thrombosis and PE, affects an estimated 900,000 people a year and causes 60,000 to 100,000 deaths, many of them sudden; in about a quarter of fatal cases, sudden death is the first sign. The yearly incidence is about 1 to 2 per 1,000 adults, and it roughly doubles with each decade after 40, so a 70-year-old carries several times the risk of a 30-year-old. Around half of episodes follow a recognizable trigger such as surgery (especially hip or knee replacement), a hospital stay, cancer, a leg fracture, pregnancy and the six weeks after delivery, or estrogen-containing contraception (pregnancy alone raises the risk about five-fold); the other half are 'unprovoked', which matters because unprovoked clots are far more likely to recur once anticoagulation stops. Survivors are not finished with it: about a third have another venous clot within ten years.
Clots form where blood is slow, the vein wall is injured, or the blood is unusually ready to clot, a combination called Virchow's triad. Most start in the deep veins of the calf; those that extend into the popliteal vein at the knee and above are the ones that break free, travel through the right side of the heart and wedge in the pulmonary arteries. Lung tissue beyond the clot is ventilated but not perfused, so oxygen levels fall, and the clot plus chemicals released by platelets abruptly raise the pressure the right ventricle must pump against. The thin-walled right ventricle tolerates this badly: it dilates, pushes the septum into the left ventricle, and cardiac output falls, which is why severe PE causes fainting and shock. On anticoagulants the body's own fibrinolytic system dissolves most of the clot over weeks, mostly within 3 months. Around half of survivors still report breathlessness or reduced exercise capacity a year later, and 2 to 4 percent develop chronic thromboembolic pulmonary hypertension, in which the clot organizes into scar inside the artery.
Diagnosis moves fast because treatment cannot wait: a clinical probability score (Wells or Geneva), a D-dimer blood test to rule PE out in low-probability patients, and a CT pulmonary angiogram to confirm it. Treatment is anticoagulation, and the 2019 European Society of Cardiology and 2021 CHEST guidelines prefer a direct oral anticoagulant over warfarin for most patients. The evidence is large: in the AMPLIFY trial, 5,395 people were randomized to apixaban or enoxaparin followed by warfarin, with recurrence of 2.3 versus 2.7 percent and major bleeding of 0.6 versus 1.8 percent; EINSTEIN-PE found the same pattern for rivaroxaban in 4,832 people. Treatment lasts at least 3 months, and indefinitely after an unprovoked PE when bleeding risk is acceptable, often at a reduced dose. Clot-dissolving thrombolysis is reserved for the roughly 5 percent of patients in shock: in the 1,006-patient PEITHO trial of intermediate-risk patients, tenecteplase cut death or hemodynamic collapse from 5.6 to 2.6 percent but raised major bleeding from 2.4 to 11.5 percent and stroke tenfold. Low-risk patients are increasingly sent home from the emergency department on a tablet.
There is no natural treatment for a pulmonary embolism, and the supplement section on this page is empty on purpose. Nattokinase, serrapeptase and lumbrokinase are sold as 'clot-dissolving enzymes'; they have laboratory fibrinolytic activity, no trials in people with DVT or PE, and the plausible harm of adding bleeding risk to an anticoagulant. Fish oil, high-dose vitamin E, garlic, ginkgo, ginger, turmeric and curcumin all inhibit platelets modestly, which is nearly irrelevant to a venous clot but relevant to bleeding on apixaban, rivaroxaban or warfarin. St. John's wort is actively dangerous: it induces the enzymes and transporter that clear rivaroxaban and apixaban, lowering their levels and leaving you unprotected. Grapefruit does the opposite. The only supplement signal is one-directional and about prevention, not treatment: in the 39,876-woman Women's Health Study, 600 IU of vitamin E on alternate days was associated with 21 percent fewer venous clots over 10 years, a finding that has never been tested as therapy and does not justify adding vitamin E to a blood thinner. The useful non-drug measures are mechanical and behavioral, listed below.
The most common fatal mistake is waiting. Breathlessness that came on over minutes to hours, especially with chest pain on breathing in, a heart rate over 100, a swollen or painful calf, or a faint, is treated as PE until proven otherwise, and the right response is 911 or the emergency department, not an urgent-care appointment tomorrow and not a web search for what to take; most deaths from PE happen within the first few hours of symptoms. The second mistake comes later: stopping the anticoagulant early because the breathlessness has settled, or because of a missed refill. Recurrence risk is highest in the first weeks, and after an unprovoked PE roughly one person in ten has another clot in the year after stopping treatment, so the decision to stop at 3, 6 or 12 months, or never, is a conversation with your clinician informed by your bleeding risk and sometimes a D-dimer, not a feeling. Carry a card or a note on your phone naming your anticoagulant; it changes what surgeons, dentists and paramedics do.
At a Glance
- Common symptoms
- Sudden shortness of breath (most common symptom), Sharp chest pain that worsens with deep breathing or coughing (pleuritic chest pain), Rapid heart rate (tachycardia)
- Main treatments
- Anticoagulation with heparin (unfractionated or low-molecular-weight) followed by oral anticoagulants (rivaroxaban, apixaban, warfarin), Systemic thrombolytics (alteplase) for massive PE with hemodynamic instability, Catheter-directed therapy for submassive PE
- Category
- Cardiovascular · Approximately 300,000–600,000 cases per year in the United States
- See a doctor if
- Sudden onset of shortness of breath (call 911)
Symptoms
Causes
- Deep vein thrombosis (DVT) — the most common source
- Other sources: fat emboli from fractures, amniotic fluid emboli, air emboli (rare)
- Blood clot formation due to Virchow's triad: stasis, endothelial injury, hypercoagulability
Risk Factors
- Recent surgery, especially orthopedic (hip, knee replacement)
- Prolonged immobility (long flights, bed rest, hospitalization)
- Cancer and chemotherapy
- Pregnancy and postpartum period
- Oral contraceptives or hormone replacement therapy
- Inherited thrombophilias (Factor V Leiden, prothrombin mutation)
Diagnosis
- CT pulmonary angiography (CTPA) — gold standard imaging
- D-dimer blood test (sensitive but not specific; useful for ruling out PE)
- Wells score or Geneva score for clinical probability assessment
- Echocardiography showing right ventricular strain (in massive PE)
- Ventilation-perfusion (V/Q) scan when CT contrast is contraindicated
Treatment
- Anticoagulation with heparin (unfractionated or low-molecular-weight) followed by oral anticoagulants (rivaroxaban, apixaban, warfarin)
- Systemic thrombolytics (alteplase) for massive PE with hemodynamic instability
- Catheter-directed therapy for submassive PE
- Inferior vena cava (IVC) filter if anticoagulation is contraindicated
- Surgical embolectomy in rare, life-threatening cases
- Long-term anticoagulation (at least 3 months; longer for unprovoked PE or recurrent events)
What matters day to day
- Walk early and often after surgery or illness: early mobilization is in every surgical clot-prevention guideline because calf muscle contraction is the main pump returning blood from the legs, and prolonged immobility is one of the strongest triggers for a first clot.
- On any journey over 4 hours, get up and walk every 1 to 2 hours, flex your ankles while seated and drink water: long-haul travel roughly doubles clot risk for several weeks afterwards, and below-knee compression stockings (15 to 30 mmHg) reduced symptomless DVT by about 90 percent in a Cochrane review of 9 trials in air passengers.
- Take the anticoagulant exactly as prescribed and set a daily alarm: apixaban and rivaroxaban wear off within about a day, so a missed dose leaves you unprotected, and rivaroxaban 15 mg and 20 mg tablets must be taken with food to be absorbed properly.
- Tell every prescriber, dentist and pharmacist that you are on an anticoagulant, and avoid ibuprofen, naproxen and aspirin unless specifically advised: non-steroidal painkillers roughly double the risk of major bleeding on a blood thinner, and acetaminophen is the safer choice for pain.
- Get back to exercise gradually once you are anticoagulated and stable: walking from the first days is safe and encouraged, structured exercise after PE improves fitness and quality of life in small trials, and obesity (BMI over 30) roughly doubles the risk of another clot, so weight is worth addressing.
- Review estrogen: combined hormonal contraception and oral menopausal hormone therapy raise clot risk 2- to 4-fold and are usually stopped after a PE, but progestin-only pills, implants and hormonal IUDs do not carry the same risk, so ask about alternatives rather than quitting contraception altogether.
Prevention
- Prophylactic anticoagulation during and after surgery or hospitalization
- Compression stockings and early ambulation post-surgery
- Moving and stretching during long flights or car rides
- Staying hydrated during travel
- Avoiding prolonged immobility
When to See a Doctor
- Sudden onset of shortness of breath (call 911)
- Sharp chest pain that worsens with breathing
- Rapid heart rate with lightheadedness or fainting
- Leg swelling and pain combined with breathing difficulty
Frequently Asked Questions
References
- Konstantinides SV, Meyer G, Becattini C, et al.. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society. European Heart Journal (2020)
- Stevens SM, Woller SC, Baumann Kreuziger L, et al.. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest (2021)
- Agnelli G, Buller HR, Cohen A, et al.. Oral apixaban for the treatment of acute venous thromboembolism (AMPLIFY). New England Journal of Medicine (2013)
- Buller HR, Prins MH, Lensin AW, et al., for the EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism (EINSTEIN-PE). New England Journal of Medicine (2012)
- Meyer G, Vicaut E, Danays T, et al.. Fibrinolysis for patients with intermediate-risk pulmonary embolism (PEITHO). New England Journal of Medicine (2014)
- Glynn RJ, Ridker PM, Goldhaber SZ, Zee RY, Buring JE. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation (2007)
- Kahn SR, Hirsch AM, Akaberi A, et al.. Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest (2017)
- Clarke MJ, Broderick C, Hopewell S, Juszczak E, Eisinga A. Compression stockings for preventing deep vein thrombosis in airline passengers. Cochrane Database of Systematic Reviews (2016)
- Centers for Disease Control and Prevention. Data and statistics on venous thromboembolism (2024)
- MedlinePlus, National Library of Medicine. Pulmonary embolism (2024)View source
Related Conditions
Lab tests that relate to pulmonary embolism
Have questions about Pulmonary Embolism?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.